<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994513</url>
  </required_header>
  <id_info>
    <org_study_id>HAC08-07-02</org_study_id>
    <nct_id>NCT00994513</nct_id>
  </id_info>
  <brief_title>Effect of Alpha Lipoic Acid on Obesity Related Comorbidities</brief_title>
  <official_title>Effect of Alpha Lipoic Acid on Obesity Related Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major objective of this study is to conduct a double-blind, placebo-controlled,
      randomized clinical trial to assess whether oral alpha lipoic acid supplementation will
      decrease cardiovascular disease and type 2 diabetes risk in obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of oxidative stress</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>alpha lipoic acid 1200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 1200 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha Lipoic Acid</intervention_name>
    <description>1200 mg/day</description>
    <arm_group_label>ALA</arm_group_label>
    <other_name>Lipoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1200 mg/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Han ethnicity

          -  BMI≥25kg/m2

          -  Having at least one of the following risk factors: borderline hypertension
             (130mmHg≤SBP&lt;140mmHg or 85mmHg≤DBP&lt;90mmHg), dyslipidemia (fasting total cholesterol
             ≥240mg/dl or HDL-C&lt;40mg/dl), or impaired fasting glucose (fasting glucose levels
             between 6.1 and 7.0mmol/L)

          -  18-60 years old

          -  Not on any antioxidant vitamin supplement

        Exclusion Criteria:

          -  Pregnancy, lactation or child-bearing age without birth control device

          -  History of hypertension, diabetes, coronary heart disease(CHD), cancer or liver
             disease

          -  Anything that would impede the subject from complying with the ALA treatment

          -  History of psychiatric problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Xiaoling Wang, Assistant Professor</name_title>
    <organization>Medical College of Georgia</organization>
  </responsible_party>
  <keyword>Antioxidant</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

